HeartSciences Inc. Files Fiscal 2026 Annual Report and Announces Proposed Fortitude Merger
Key Highlights from the Report
- HeartSciences Inc. (Nasdaq: HSCS; HSCSW), a healthcare information technology company specializing in AI-powered electrocardiography (ECG/EKG), has filed its Annual Report on Form 10-K for the fiscal year ended April 30, 2026.
- The company is preparing to file a preliminary proxy statement with the SEC in connection with a proposed business combination with Fortitude Mining Holdings, Inc. (“Fortitude”), a major player in institutional-scale, vertically integrated venture mining focused on Proof-of-Work cryptocurrencies, especially Zcash.
- HeartSciences believes the Fortitude merger represents a significant opportunity for shareholders, offering continued ownership in a scaled, revenue-generating business backed by Digital Currency Group (DCG), while allowing HeartSciences’ flagship MyoVista Insights AI-ECG technology to advance with greater focus.
- After the proxy statement filing, HeartSciences plans to release its fiscal 2026 earnings and provide a business update, expected early next week.
Important Information for Shareholders
- The Proposed Transaction: HeartSciences is seeking shareholder approval for a merger with Fortitude Mining Holdings, Inc., which is currently wholly owned by DCG. This merger could substantially alter the company’s business profile, combining healthcare AI technology with institutional cryptocurrency mining.
- Potential Price Sensitivity: The merger is described as a “significant value creation opportunity” for HeartSciences shareholders. If approved and completed, shareholders will benefit from ownership in a company with established revenue streams and the backing of a respected institutional investor. The transaction could also affect share prices due to expected synergies, revenue growth, and exposure to the volatile cryptocurrency sector (especially Zcash).
- Risks and Uncertainties: The press release notes several risks, including the possibility that the merger may not close as anticipated or at all, failure to obtain shareholder approval, integration risks, exposure to cryptocurrency volatility (especially Zcash), and regulatory uncertainties related to digital assets. These factors could materially affect shareholder value and future share price performance.
- Shareholder Participation: HeartSciences and Fortitude, as well as certain officers and directors of DCG, may be deemed participants in the proxy solicitation. Shareholders are encouraged to review all SEC filings related to the merger before making any voting or investment decisions.
- SEC Filings: All relevant documents, including the proxy statement and further details about the merger, will be available at www.sec.gov and from HeartSciences’ investor relations.
Detailed Analysis of the Proposed Merger
The proposed merger between HeartSciences and Fortitude brings together two innovative companies from distinct sectors: healthcare information technology and institutional cryptocurrency mining. Fortitude operates across the Proof-of-Work ecosystem, anchored in Zcash, and pairs self-mining operations with its own data center footprint and diversified power portfolio. The company is led by experienced operators, capital markets professionals, and digital asset specialists with a record of scaling high-conviction opportunities in emerging crypto sectors.
HeartSciences’ MyoVista Insights AI-ECG platform, which launched in fiscal 2026, is a device-agnostic next-generation ECG management system designed to improve clinical efficiency and decision-making. The MoVista wavECG device delivers conventional ECG functionality while enabling on-device AI solutions, positioning HeartSciences as a leader in AI-driven diagnostic technology.
CEO Andrew Simpson described fiscal 2026 as a “landmark year” due to the launch of MyoVista Insights and the transition to mainstream commercial revenue. Simpson emphasized the value creation potential of the Fortitude merger and encouraged shareholders to review the proxy statement for detailed information about the proposed transaction.
The merger, if completed, would give HeartSciences shareholders continued ownership in a company with meaningful, scalable revenue generation and the backing of Digital Currency Group, a major institutional investor. Importantly, it would allow HeartSciences to focus its resources on advancing the MyoVista technology, potentially accelerating commercialization and market adoption.
However, the press release cautions investors about several risks: the possibility that the transaction may not be completed, integration challenges, exposure to cryptocurrency volatility, and legal and regulatory uncertainties. Shareholders should be aware that HeartSciences and Fortitude expressly disclaim any obligation to update forward-looking statements except as required by law.
Next Steps for Investors and Shareholders
- HeartSciences will soon file a preliminary proxy statement with the SEC detailing the merger terms and implications for shareholders.
- A definitive proxy statement will then be sent to shareholders, who will be asked to vote at a special meeting.
- Shareholders are urged to read all relevant SEC filings and proxy materials before making any decisions regarding the merger.
- HeartSciences’ investor relations team is available for questions and additional information.
Contact Information
Investor Relations:
Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: [email protected]
Disclaimer
This article is for informational purposes only and does not constitute investment advice, solicitation, or an offer to buy or sell securities. Forward-looking statements in this article are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. Investors should review all relevant SEC filings and consult their financial advisors before making investment decisions.
